INFORMATIVE DROPOUT MODELING AND EXPOSURE-RESPONSE ANALYSIS FOR MAVRILIMUMAB PHASE IIB STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS.

被引：0
|
作者：
Wu, C. [1 ]
Jin, C. D. [1 ]
Roskos, L. [2 ]
Wang, B. [1 ]
机构：
[1] AstraZeneca MedImmune, Mountain View, CA USA
[2] AstraZeneca MedImmune, Gaithersburg, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-055
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [1] Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout.
    Wu, Chi-Yuan
    Jin, Denise
    Godwood, Alex
    Close, David
    Roskos, Lorin
    Wang, Bing
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S658 - S658
  • [2] A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
    Weinblatt, Michael E.
    McInnes, Iain B.
    Kremer, Joel M.
    Miranda, Pedro
    Vencovsky, Jiri
    Guo, Xiang
    White, Wendy I.
    Ryan, Patricia C.
    Godwood, Alex
    Albulescu, Marius
    Close, David
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (01) : 49 - 59
  • [3] Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis
    Toyoshima, Junko
    Kaibara, Atsunori
    Shibata, Mai
    Kaneko, Yuichiro
    Izutsu, Hiroyuki
    Nishimura, Tetsuya
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (03):
  • [4] Population Approach for Exposure-Response Modeling of Golimumab in Patients With Rheumatoid Arthritis
    Hu, Chuanpu
    Xu, Zhenhua
    Zhang, Yi
    Rahman, Mahboob U.
    Davis, Hugh M.
    Zhou, Honghui
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (05): : 639 - 648
  • [5] Exposure-Response Modeling and Power Analysis of ACR Core Components in Rheumatoid Arthritis
    Zhang, Yi
    Ma, Lian
    Ji, Ping
    Yim, Sarah
    Doddapaneni, Suresh
    Liu, Jiang
    Dinko, Rekic
    Brar, Satjit
    Wang, Yaning
    Sahajwalla, Chandrahas
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S68 - S68
  • [6] Exposure-Response Modeling and Simulation of the Efficacy Endpoints in Rheumatoid Arthritis
    Ma, Lian
    Ji, Ping
    Wang, Yaning
    Zhao, Liang
    Xu, Yun
    Doddapaneni, Suresh
    Sahajwalla, Chandrahas G.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S73 - S73
  • [7] EXPOSURE-EFFICACY ANALYSIS OF MAVRILIMUMAB IN RHEUMATOID ARTHRITIS: MODELING AND SIMULATION OF PHASE II CLINICAL DATA
    Jin, D. C.
    Wu, C. -Y.
    Roskos, L. K.
    Godwood, A.
    Close, D.
    Wang, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1043 - 1043
  • [8] Longitudinal exposure-response analysis of CDAI score in rheumatoid arthritis patients treated with sirukumab
    Xu, Yan
    Hu, Chuanpu
    Zhuang, Yanli
    Hsu, Benjamin
    Xu, Zhenhua
    Sharma, Amarnath
    Zhou, Honghui
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S121 - S121
  • [9] Longitudinal Abatacept Exposure-Response Characterization in Japanese Rheumatoid Arthritis Patients
    Hasegawa, Mayumi
    Hiraoka, Masaki
    Ito, Kiyomi
    Roy, Amit
    Imai, Yasuhiko
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1327 - 1327
  • [10] Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients
    Wang, Huanhuan
    Hu, Xiaoyun
    Wang, Teng
    Cui, Cheng
    Jiang, Ji
    Dong, Kai
    Chen, Shuai
    Jin, Chunyan
    Zhao, Qian
    Du, Bin
    Hu, Pei
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345